Health Secretary Defends Response to Kent Meningitis B Outbreak Linked to Super-Spreader

Health Secretary Defends Response to Kent Meningitis B Outbreak Linked to Super-Spreader

Health Secretary Wes Streeting has defended the government's response to what he describes as an "unprecedented" meningitis B outbreak in Kent, which has been linked to a suspected super-spreader event and resulted in two fatalities. Streeting asserted that the UK Health Security Agency (UKHSA) acted "as quickly and as comprehensively as possible" amid criticism over the timing of public alerts.

Rising Cases and Targeted Vaccinations

Confirmed cases in the outbreak have increased from 13 to 15, with all patients currently hospitalised. The infections are associated with the meningitis B strain and have been traced to the University of Kent and at least four schools, with a potential fifth school case under investigation. In response, a targeted vaccination drive has been urgently implemented for students at the University of Kent, and 700 doses of antibiotics have been distributed to curb further transmission.

Health sources indicate that the outbreak is unprecedented due to the rapid emergence of cases, all linked to the Chemistry nightclub in Canterbury and the university. One source stated, "It looks like a super-spreader event." The victims include an 18-year-old pupil named Juliette and an unnamed 21-year-old university student.

—

Timeline of the Outbreak and Public Health Measures

Streeting outlined the timeline, noting that UKHSA was informed of the first case on Friday, with close contacts immediately offered prophylactic antibiotics. On Saturday, French health authorities alerted UKHSA to a second case in France involving someone who had attended the University of Kent. Although further symptomatic individuals were identified by 7pm that day, the public health alert was not issued until 6pm.

"This is an unprecedented outbreak. It is also a rapidly developing situation," Streeting said. "It is important that the House [of Commons] and wider public understand, even before the public health alert was issued, students and young people who had been in close contact were being offered antibiotics. This is precisely what you would expect in a rapid response."

Vaccination Challenges and Ethical Concerns

The UKHSA has launched a vaccination programme for students in Canterbury halls of residence, but a surge in private vaccine demand has led to shortages in some Kent pharmacies, according to Dr Leyla Hannbeck, CEO of the Independent Pharmacies Association. Reports have emerged of pharmacies allegedly price-gouging, with vaccines being sold for "several hundred pounds." Streeting condemned this as "immoral" and advised against private purchases, emphasising that health authorities do not recommend it.

The menB vaccine has been available on the NHS since 2015 as part of routine childhood immunisations, leaving many older children and university students unvaccinated. Streeting has requested the Joint Committee on Vaccination and Immunisation (JCVI) to re-examine eligibility for meningitis vaccines, following a previous ruling that a catch-up campaign for older children was not cost-effective.

Expert Insights on Transmission and Containment

Epidemiologists have raised concerns about the vaccine's effectiveness and cost. Keith Neal, emeritus professor at the University of Nottingham, noted that the menB vaccine is expensive and does not prevent transmission, unlike the ACWY vaccine. "It is an expensive vaccine, and there are better things to spend the NHS budget on," he said.

However, experts believe the outbreak is unlikely to spread nationally. Professor Adam Finn, a former JCVI member, explained that antibiotics can "kill the bug in [people's] noses and throats, and so it stops them getting sick and stops them infecting other people." He added, "As long as people get them [antibiotics], it [the outbreak] will snuff out."

Professor Ian Jones of Reading University reinforced this, stating that meningitis outbreaks typically remain localised and can be managed with prompt treatment and symptom awareness. Meanwhile, Dr Michael Head from the University of Southampton highlighted uncertainties about the specific serotype, suggesting it may have mutations causing more severe illness. Health officials are conducting genome sequencing to identify the variant.